Centre Hospitalier Universitaire de Nancy / CHU Hôpitaux de Brabois

Microdeletions at 19p13.11p12 in five individuals with neurodevelopmental delay (2023) Rieger M, Moutton S, Verheyen S, Steindl K, Popp B, Leheup B, Bonnet C, et al. Journal article Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (2022) Burchert A, Saussele S, Michel C, Metzelder SK, Hochhaus A, Gattermann N, Crysandt M, et al. Conference contribution HIGH CHOLESTEROL ABSORPTION IS ASSOCIATED WITH INCREASED CARDIOVASCULAR RISK IN HEMODIALYSIS PATIENTS: INSIGHTS FROM THE AURORA STUDY (2022) Silbernagel G, Duarte K, Sadiku S, Fauler G, Maerz W, Schmieder R, Jardine AG, et al. Conference contribution Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis (2022) Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, et al. Journal article, Review article Seizure semiology: ILAE glossary of terms and their significance (2022) Beniczky S, Tatum WO, Blumenfeld H, Stefan H, Mani J, Maillard L, Fahoum F, et al. Journal article High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study (2022) Silbernagel G, Duarte K, Sadiku S, Fauler G, Maerz W, Schmieder R, Jardine AG, et al. Journal article Microdeletions at 19p13.11 in four individuals with neurodevelopmental delay (2022) Rieger M, Moutton S, Verheyen S, Speicher M, Leheup B, Bonnet C, Steindl K, et al. Conference contribution CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease (2022) Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, et al. Journal article A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis (2022) Peyrin-Biroulet L, Arkkila P, Armuzzi A, Atreya R, Danese S, Ferrante M, Guardiola J, et al. Conference contribution Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative (2021) Kayser S, Schlenk RF, Lebon D, Carre M, Goetze KS, Stoelzel F, Berceanu A, et al. Journal article